| [1] |
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia [J]. Obstet Gynecol，2019，133(1):e1-e25.
|
| [2] |
Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance [J]. BMJ, 2019, 366:1-8.
|
| [3] |
中华医学会妇产科学会分会妊娠期高血压疾病学组．妊娠期高血压疾病诊治指南(2020)[J]. 中华妇产科杂志，2020, 55(4): 227-238.
|
| [4] |
Boutin A, Gasse C, Demers S, et al. Maternal Characteristics for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes (GOS) Study [J]．J Obstet Gynaecol Can, 2018, 40(5):572-578.
|
| [5] |
O′Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks′ gestation: comparison with NICE guidelines and ACOG recommendations [J]. Ultrasound Obstet Gynecol, 2017, 49(6):756-760.
|
| [6] |
苏镇培．谈"平均动脉压"——兼答读者问[J]．中华高血压杂志，2015, 23(8):719-721.
|
| [7] |
Poon LC, Kametas NA, Valencia C, et al. Hypertensive Disorders in Pregnancy: Screening by Systolic Diastolic and Mean Arterial Pressure at 11-13 Weeks [J]. Hypertension in Pregnancy, 2011, 30(1):93-107.
|
| [8] |
Gasse C, Boutin A, Cote M, et al. First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study [J]. Pregnancy Hypertens，2018，12:178-182.
|
| [9] |
Rocha RS, Alves JAG, Maia E, Holanda Moura SB, et al. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy[J]. J Perinat Med, 2017，45(7):843-849.
|
| [10] |
Agrawal S, Shinar S, Cerdeira AS, et al. Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women: A Systematic Review and Meta-Analysis [J]. Hypertension, 2019，74(5):1124-1135.
|
| [11] |
Boutin A, Demers S, Gasse C, et al. First-Trimester Placental Growth Factor for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes Cohort Study [J]. Fetal Diagn Ther, 2019, 45(2):69-75.
|
| [12] |
Agrawal S, Cerdeira AS, Redman C, et al. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study [J]. Hypertension, 2018, 71(2): 306-316.
|
| [13] |
Bian X, Biswas A, Huang X, et al. Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia [J]. Hypertension, 2019, 74(1):164-172.
|
| [14] |
Boutin A, Gasse C, Demers S, et al. Does Low PAPP-A Predict Adverse Placenta-Mediated Outcomes in a Low-Risk Nulliparous Population? the Great Obstetrical Syndromes (GOS) Study [J]. J Obstet Gynaecol Can, 2018, 40(6):663-668.
|
| [15] |
De Villiers CP, Hedley PL, Placing S, et al. Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia [J]. Clin Chem Lab Med, 2017, 56(1):65-74.
|
| [16] |
刘楼，许建娟，孙丽洲. 彩色多普勒超声测定胎盘商与胎盘蛋白-13联合筛查预测子痫前期的价值 [J]．中华超声影像学杂志，2016, 25(5): 453-454.
|
| [17] |
Demers S, Boutin A, Gasse C, et al. First-Trimester Uterine Artery Doppler for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndrome Study [J]. Am J Perinatol, 2019, 36(9):930-935.
|
| [18] |
González-González NL, González Dávila E, Padrón E, et al. Value of Placental Volume and Vascular Flow Indices as Predictors of Early and Late Preeclampsia at First Trimester [J]. Fetal Diagn Ther, 2018, 44(4):256-263.
|
| [19] |
Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers [J]. Fetal Diagn Ther, 2013, 33(1): 8-15.
|
| [20] |
Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE[J]. Ultrasound Obstet Gynecol, 2018, 51(6): 743-750.
|
| [21] |
Risk for preeclampsia[DB/OL]．London：Fetal Medicine Fundation，2021[2021-08-20].
URL
|
| [22] |
Chaemsaithong P, Pooh RK, Zheng M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population[J]. Am J Obstet Gynecol, 2019, 221(6): 650.e1-650.e16.
|
| [23] |
O′gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks′ gestation: comparison with NICE guidelines and ACOG recommendations[J]. Ultrasound Obstet Gynecol, 2017, 49(6): 756-760.
|
| [24] |
Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention[J]. Int J Gynaecol Obstet, 2019, 145 Suppl 1(Suppl 1): 1-33.
|
| [25] |
Von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model[J]. Lancet, 2011, 377(9761): 219-227.
|
| [26] |
Thangaratinam S, Allotey J, Marlin N, et al. Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models[J]. BMC Med, 2017, 15(1): 68.
|